News

Merck: Best Case For Option Collars We'll Ever See
Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...
Fierce Biotech1d
Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Fierce Pharma1d
Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Merck & Co., Inc. ( NYSE: MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M. Davis - ...
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...
Zacks Investment Research on MSN3h
Merck (MRK) Rises Higher Than Market: Key Facts
The most recent trading session ended with Merck (MRK) standing at $81.35, reflecting a +2.55% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55%.
Fierce Pharma1d
FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer
When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...
BioPharma Dive1d
Merck claims study success with PCSK9 cholesterol pill
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Merck's Keytruda
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...